These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25272050)

  • 1. A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates.
    Abrams MT; Koser M; Burchard J; Strapps W; Mehmet H; Gindy M; Zaller D; Sepp-Lorenzino L; Stickens D
    Nucleic Acid Ther; 2014 Dec; 24(6):405-12. PubMed ID: 25272050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
    Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
    J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
    Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
    Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia.
    Soni H
    Med Hypotheses; 2014 May; 82(5):547-50. PubMed ID: 24581673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
    Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the role of the HIF hydroxylase family members in erythropoiesis.
    Fisher TS; Lira PD; Stock JL; Perregaux DG; Brissette WH; Ozolins TR; Li B
    Biochem Biophys Res Commun; 2009 Oct; 388(4):683-8. PubMed ID: 19683512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
    Flamme I; Ellinghaus P; Urrego D; Krüger T
    PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
    J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury.
    Xie D; Wang J; Hu G; Chen C; Yang H; Ritter JK; Qu Y; Li N
    J Pharmacol Exp Ther; 2021 Sep; 378(3):235-243. PubMed ID: 34103333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
    Shinfuku A; Shimazaki T; Fujiwara M; Sato F; Watase H; Numazaki T; Kawakita Y; Mutoh M; Yamasaki H; Takayama N; Kato S; Sugimoto T; Maruyama J
    Am J Nephrol; 2018; 48(3):157-164. PubMed ID: 30176654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U
    PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematological, hepatic, and retinal phenotypes in mice deficient for prolyl hydroxylase domain proteins in the liver.
    Duan LJ; Takeda K; Fong GH
    Am J Pathol; 2014 Apr; 184(4):1240-1250. PubMed ID: 24508125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
    Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
    Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of erythropoietin deficiency in mice with systemically administered siRNA.
    Querbes W; Bogorad RL; Moslehi J; Wong J; Chan AY; Bulgakova E; Kuchimanchi S; Akinc A; Fitzgerald K; Koteliansky V; Kaelin WG
    Blood; 2012 Aug; 120(9):1916-22. PubMed ID: 22611156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
    Maxwell PH; Eckardt KU
    Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.